



National Institute of  
Environmental Health Sciences  
*Division of the National Toxicology Program*

# Carcinogenicity Testing for the 21st Century

**Warren Casey, PhD, DABT**


**Chief (Acting), Predictive Toxicology Branch**

**NIEHS / DNTP**

05.26.2022

## Guidelines for Rodent Carcinogenicity Studies

Protocols for conducting carcinogenicity testing in rodents were developed  
> 50 years ago and remain virtually unchanged.



OPPTS 870.4200 Carcinogenicity

OECD TG 451: Carcinogenicity Studies

ICH S1 Carcinogenicity testing guidelines

~1000 animals per study







## Advances in Science and Technology

- In Vitro model systems (2D, 3D, MPS, iMPS)
- Collection and access to human cancer tissue samples
- Metabolomics / Proteomics / Transcriptomics
- NextGen / Whole Genome Sequencing
- (Big) Data collection, warehousing, sharing and development of bioinformatic tools: Pan-Cancer Atlas, TCGA, COSMIC, ICGC-PCAWG, etc....
- Machine Learning / Artificial Intelligence and Computational Modeling

# Advances in Understanding Human Cancer Biology

Improved understanding of human cancers (> > rodent)


- Oncogenic Signaling Pathways
- Hallmarks of Cancer / Key Characteristics of Carcinogens
- Cancer Driver Genes and Mutational Signatures





# New Regulatory Environment

- EPA initiatives
- FDA initiatives
- Interagency and International efforts




EPA United States Environmental Protection Agency  
Search EPA.gov

Environmental Topics ▾ Laws & Regulations ▾ Report a Violation ▾ About EPA ▾

Related Topics: [Safer Chemicals Research](#) CONTACT US

## EPA New Approach Methods Work Plan: Reducing Use of Vertebrate Animals in Chemical Testing




- **Mission**


- To improve public health through the development of **data** and **knowledge** that are **translatable, predictive and timely**.


- **Goals**

- **Lead** the transformation of toxicology through the development and application of innovative tools and strategies.
- **Collaborate** with public stakeholders and global partners to identify and address public health issues.
- Generate and **communicate** trusted scientific information to support decision making on environmental hazards of public interest.
- **Educating** and **training** the next generation of translational scientists to be innovative leaders in the field.



“Lead the transformation of toxicology through the development and application of **innovative** tools and strategies.”








## Goals of the Carci-HEI

- Shorten time to report trusted and actionable information
- Improve confidence in relevance to human health, especially in susceptible or disproportionately affected populations
- Reduce or eliminate reliance on animal models

## Translational Toxicology Pipeline

- Portfolio of technical capabilities
- Deliberate and integrated use
- Opportunity for iterative learning
- Focus on human condition and all it's complexities




## Provide resources to make existing information on carcinogens Findable, Accessible, Interoperable and Reusable (FAIR)

- Curated data and search tools
  - Organized by toxicity endpoints
  - Standardized terminology, units, and formatting
- Curated chemical lists
  - Reference lists with classifications and bioactivity
  - In vitro assays linked with defined terminology
- Computational models
  - In vitro to in vivo extrapolation (IVIVE)
  - Quantitative structure-activity relationship (QSAR) models



Integrated  
Chemical  
Environment



<https://ice.ntp.niehs.nih.gov/>

## Chemical Lists

- Tox21 i
- AR In Vitro Agonist (R) i
- AR In Vitro Antagonist (R) i
- AR In Vivo Agonist i
- AR In Vivo Antagonist i
- EPA IRIS Carcinogenicity Classifications i
- EPA Pesticide Active Ingredients i
- EPA Pesticide Inert Ingredients, Food and Nonfood Use i
- ER In Vitro Agonist (R) i
- ER In Vivo Agonist (R) i
- Eye Irritation-Corrosion (R) i
- Genotoxicity (R) i
- IARC Classifications i
- NTP Cancer Bioassay Chemicals i
- RoC Classifications i
- Skin Corrosion (R) i
- Steroidogenesis - Androgen i
- Steroidogenesis - Estrogen i
- Thyroid i

CASRN	Chemical Name	DTXSID	Original SMILES	Original InChIKey	QSAR Ready SMILES	Technical Report No.	NTP Level Of Evidence Male Rats	NTP Level Of Evidence Female Rats	NTP Level Of Evidence Male Mice	NTP Level Of Evidence Female Mice	Tested in Tox21
67-66-3	Chloroform	DTXSID1020306	ClC(Cl)Cl	HEDRZPFGACZZDS-UHFFFAOYSA-N	ClC(Cl)Cl	TR-000	P	NE	P	P	Yes
143-50-0	Chlordecone (kepone)	DTXSID1020770	ClC12C(=O)C3(C)C4(C)C1(Cl)C1(C)C2(C)C3(C)C4(C)C1(Cl)C1(Cl)	LHHGDZSESBACKH-UHFFFAOYSA-N	ClC12C(=O)C3(C)C4(C)C1(C)C1(C)C2(C)C3(C)C4(C)C1(Cl)C1(Cl)	TR-001	P	P	P	P	Yes
79-01-6	Trichloroethylene	DTXSID0021383	ClC=C(Cl)Cl	XSTXAVWGKQKEL-UHFFFAOYSA-N	ClC=C(Cl)Cl	TR-002	NE	NE	P	P	Yes

- genotoxicity data
- highest dose tested
- dose and tissue used for level of evidence call
- type of lesion



## Tox21 HTS assays mapped to Key Characteristics of Carcinogens (KCC)

<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>				
cHTS	Acute Lethality	Sensitization	Irritation/Corrosion	Endocrine	Cancer	DART	Chemical Parameters
<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>				
					▼ Cancer		
<input type="checkbox"/>	▼ Mode of Action	<input type="checkbox"/>	<input type="checkbox"/>				
<input type="checkbox"/>	<input checked="" type="checkbox"/> KCC1: Electrophilic/Metabolically Activated	<input type="checkbox"/>	<input type="checkbox"/> in vitro				
<input type="checkbox"/>	<input checked="" type="checkbox"/> KCC2: Genotoxic Effects	<input type="checkbox"/>	<input type="checkbox"/> in vitro				
<input type="checkbox"/>	<input checked="" type="checkbox"/> KCC3: Alteration of DNA Repair/Genomic Stability	<input type="checkbox"/>	<input type="checkbox"/> in vitro				
<input type="checkbox"/>	<input checked="" type="checkbox"/> KCC4: Epigenetic Alterations	<input type="checkbox"/>	<input type="checkbox"/> in vitro				
<input type="checkbox"/>	<input checked="" type="checkbox"/> KCC5: Oxidative Stress	<input type="checkbox"/>	<input type="checkbox"/> in vitro				
<input type="checkbox"/>	<input checked="" type="checkbox"/> KCC6: Chronic Inflammation	<input type="checkbox"/>	<input type="checkbox"/> in vitro				
<input type="checkbox"/>	<input checked="" type="checkbox"/> KCC8: Receptor Mediated Effects	<input type="checkbox"/>	<input type="checkbox"/> in vitro				
<input type="checkbox"/>	<input checked="" type="checkbox"/> KCC10: Cell Proliferation/Death/Energetics	<input type="checkbox"/>	<input type="checkbox"/> in vitro				

## Chemical Lists

- Tox21 i
- AR In Vitro Agonist (R) i
- AR In Vitro Antagonist (R) i
- AR In Vivo Agonist i
- AR In Vivo Antagonist i
- EPA IRIS Carcinogenicity Classifications i
- EPA Pesticide Active Ingredients i
- EPA Pesticide Inert Ingredients, Food and Nonfood Use i
- ER In Vitro Agonist (R) i
- ER In Vivo Agonist (R) i
- Eye Irritation-Corrosion (R) i
- Genotoxicity (R) i
- IARC Classifications i
- NTP Cancer Bioassay Chemicals i
- RoC Classifications i
- Skin Corrosion (R) i
- Steroidogenesis - Androgen i
- Steroidogenesis - Estrogen i
- Thyroid i

## Tox21 HTS assays mapped to Key Characteristics of Carcinogens (KCC)

cHTS
Acute Lethality
Sensitization
Irritation/Corrosion
Endocrine
Cancer
DART
Chemical Parameters

i ▼ Cancer

▼ Mode of Action

<span style="font-size: 0.8em;">i</span>	KCC1: Electrophilic/Metabolically Activated	in vitro
<span style="font-size: 0.8em;">i</span>	KCC2: Genotoxic Effects	in vitro
<span style="font-size: 0.8em;">i</span>	KCC3: Alteration of DNA Repair/Genomic Stability	in vitro
<span style="font-size: 0.8em;">i</span>	KCC4: Epigenetic Alterations	in vitro
<span style="font-size: 0.8em;">i</span>	KCC5: Oxidative Stress	in vitro
<span style="font-size: 0.8em;">i</span>	KCC6: Chronic Inflammation	in vitro
<span style="font-size: 0.8em;">i</span>	KCC8: Receptor Mediated Effects	in vitro
<span style="font-size: 0.8em;">i</span>	KCC10: Cell Proliferation/Death/Energetics	in vitro

**Data**






## HepaCometChip

**NIEHS SBIR (U44): Development of a high throughput DNA damage assay in hepatocytes**

*Reducing the Use of Animals in  
Research via New Alternative  
Methodology (NAM)*

Microwell array technology  
enables higher throughput  
and more robust  
measurements of  
genotoxicity in hepatocytes.



**Prof. Bevin Engelward**

Director, MIT Superfund Research Program  
Dept. of Biological Engineering, MIT




**Dr. Les Recio**


Chief Scientific Officer  
ScitoVation



## Translational Toxicology Pipeline



## Translational Toxicology Pipeline





THE WHITE HOUSE



[Administration](#)

[Priorities](#)

[COVID Plan](#)

[Briefing Room](#)

[Español](#)

BRIEFING ROOM

## Fact Sheet: President Biden Reignites Cancer Moonshot to End Cancer as We Know It

FEBRUARY 02, 2022 • STATEMENTS AND RELEASES

*“Biden-Harris Administration Sets Goal of Reducing Cancer Death Rate by at least 50 Percent Over the Next 25 Years, and Improving the Experience of Living with and Surviving Cancer”*



## Goals include..

- **To diagnose cancer sooner** — Detecting and diagnosing cancers earlier means there may be more effective treatment options. Five years ago, detecting many cancers at once through blood tests was a dream. Now new technologies could put this within our reach.
- **To prevent cancer** — According to the WHO, Between 30-50% of all cancer cases are preventable. Prevention offers the most cost-effective long-term strategy for the control of cancer.



**Colonel Craig D. Shriver, MD**

Director of the Clinical Breast Care Project (CBCP)  
as well as the Director of the John P. Murtha Cancer  
Center at Walter Reed National Military Medical  
Center.




**Department of Defense Serum Repository**



**Pacific Northwest**  
NATIONAL LABORATORY

# Translational Research: Linking Exposures to Disease





# Carci HEI Program Management Team Members



**Amy Wang**  
Integrative Health  
Assessments Branch



**Julie Foley**  
Mechanistic Toxicology  
Branch




**Arun Pandiri**  
Comparative and Molecular  
Pathogenesis Branch



**Dave Gerhold**  
National Center for Advancing  
Translational Sciences



**Erik Tokar**  
Mechanistic Toxicology Branch



**Warren Casey**  
Predictive Toxicology Branch



**Kristine Witt**  
NIEHS Retired, Special Volunteer



National Institute of  
Environmental Health Sciences

*Division of the National Toxicology Program*

Thank you!